Tag Archives: Partnership

December 18, 2020
In The News

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents.

Read Article
December 18, 2020
FeaturedPress Release

A2i Therapeutics secures seed funding from FutuRx and its investors – Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures, OrbiMed Partners, Leaps by Bayer and the Israeli Innovation Authority – to develop novel small molecule immuno-oncology agents. SAN FRANCISCO, CA and NESS ZIONA, Israel – December  18, 2020 – Atomwise, the leader in using artificial […]

Read Article
October 6, 2020
In The News

Atomwise announced today $2.3M in grant funding for AI-based discovery of antimalarial and anti-tuberculosis therapies.

Read Article
October 6, 2020
FeaturedPress Release

The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the foundation’s global network SAN FRANCISCO, CA — October 6th, 2020 — Atomwise, the leader in using artificial intelligence (AI) for small […]

Read Article
September 23, 2020
In The News

[Hemophilia News Today] Atomwise, a company that specializes in using artificial intelligence (AI) to develop small molecule medicines, will partner with GC Pharma to discover new ways of treating people with hemophilia. 

Read Article
September 11, 2020
In The News

[Korea Biomedical Review] GC said that it has partnered with Atomwise, a U.S. artificial intelligence-based drug development firm, to discover a new treatment candidate for hemophilia.

Read Article